Prostate Cancer Clinical Trials in Boston

Showing 21-40 of 221 trials

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

NCT06463457

This research study is being done to determine the rate of testosterone recovery after completing two years of treatment with the combination of relugolix and darolutamide as well as to assess the safety of the drugs when administered in combination. The names of the drugs in this study are: * Relugolix (a type of gonadotropin-releasing hormone receptor antagonist) * Darolutamide (a type of androgen receptor antagonist)

Prostate CancerAdvanced Prostate CancerHormone Sensitive Prostate Cancer

Atish Choudhury, MD33 participantsStarted Dec 2024

Boston, Massachusetts, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States

COMPLETEDPhase 3< 1 mile

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

NCT00936390

RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective with or without androgen-deprivation therapy in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.

Prostate Cancer

Radiation Therapy Oncology Group1,538 participantsStarted Sep 2009

Birmingham, Alabama, United States • Fairbanks, Alaska, United States • Peoria, Arizona, United States +515 more locations

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Prostate Cancer Trials in Other Cities

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Video Education With Result Dependent dIsclosure

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Other Conditions in Boston